$Sangamo Therapeutics Inc(SGMO)$
πΊππΉπ π €π π π π ’π ππΉ Positions opened NZ π³πΏ time 17Dec24 @$2.64
π π $SGMO: Supercycle Awakening, History Set to Repeat? ππ₯
Sangamo Therapeutics ($SGMO) is showing signs of life as we edge out of its super cycle correction delay π. Historically, SGMOβs chart has delivered massive spikes, cycling through lows before explosive moves to the upside.
π π Key Levels to Watch:
β’ Holding support around $2.50 to $2.60.
β’ Resistance levels in the $6 to $8 zone could trigger a parabolic rally.
π‘ Analyst Insight:
Sangamo Therapeutics (SGMO) has an average rating of overweight and a mean price target of $6.33, according to analysts polled by FactSet.
π― Fun Fact:
Sangamo was the first company to clinically test zinc-finger nuclease technology, a pioneering gene-editing tool that paved the way for advancements in genetic research. π§¬
π₯ππππ£π£οΈπ’ History Speaks:
Look at those 2013, 2018 peaks, similar patterns shaping up now! If momentum builds and volume supports, this setup could get crazy once again.
β βΆοΈ Play the cycle smart, itβs been a long nap π€, but the wake-up call may be here. πποΈπ
Happy trading ahead! Cheers, BC πππ
@Tiger_comments @TigerStars @TigerPicks @TigerPM @Daily_Discussion @TigerGPT
Modify on 2024-12-17 01:52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Sangamo Therapeutics Inc (SGMO) has shown signs of life as it emerges from its super cycle correction delay. Historically, SGMO's chart has experienced massive spikes, cycling through lows before explosive moves to the upside. Currently, there is no specific news or information available that explains the recent movement of SGMO's stock price. It is important to note that stock movements can be influenced by various factors, including market sentiment, investor activity, and overall market conditions.
However, it is worth mentioning that analysts polled by FactSet have an average rating of "overweight" for Sangamo Therapeutics (SGMO), with a mean price target of $6.33. This suggests optimism among analysts regarding the company's future prospects.
Furthermore, it is interesting to note that Sangamo Therapeutics was the first company to clinically test zinc-finger nuclease technology, a pioneering gene-editing tool that has paved the way for advancements in genetic research.
Overall, while there are no specific news articles explaining the recent movement of SGMO's stock price, it is important to consider the broader market conditions and factors that could be influencing the stock's movement. As always, it is recommended to conduct thorough research and analysis before making any investment decisions.
Note: The information provided is for reference purposes only and does not constitute investment advice. Trading stocks involves risks, and it is important to perform your own due diligence and consult with a financial advisor before making any investment decisions.
Looks like a low cost winner BC! Shared! ππ
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?